Villela LM, Bolaños-Meade J

Language: Spanish
References: 20
Page: 86-89
PDF size: 70.72 Kb.

ABSTRACT

The effective prevention of graft-versus-host disease is one of the biggest challenges for the stem cell transplant physician. While there are schemas that are quite similar in their results (and these are deemed “acceptable”), these are associated with prolonged immunosupression and relatively high rates of chronic graft-versus-host disease. The use of high dose cyclophosphamide (50/kg/day on days +3 and +4) are associated with low rates of acute graft-versus-host disease (particularly grades III and IV) as well as low rates of chronic graft-versus-host disease (around 10%) allowing transplants even between mismatched and haploidentical, donor-recipient pairs. In this review the results using this approach are reviewed with particular attention to the potential benefits for patients transplanted in Mexico.

REFERENCES

1. Bolaños-Meade J, Vogelsang GB. Acute graft-versus-host disease. Clinical Advances in Hematology & Oncology 2004;2(10):672-682.

2. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005;106(9):3308-3313.

3. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98(10):2942-2947.

4. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373(9674):1550-1561.

5. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128(2):255-266.

6. Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamidebased chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2002; 49(4):309-321.

7. Jones RJ, Barber JP, Vala MS et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85(10):2742-2746.

8. Brodsky RA, Sensenbrenner LL, Smith BD et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001; 135(7):477-483.

9. Owens AH, Santos GW. The effect of cytotoxic drugs on graftversus-host disease in mice. Transplantation 1971;11(4):378-382.

10. Glucksberg H, Fefer A. Chemotherapy of established graftversus- host disease in mice. Transplantation 1972; 13(3):300-305.

11. Santos GW, Tutschka PJ, Brookmeyer R. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized, double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987;1:21-28.

12. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and postransplantation cyclophosphamide. Blood 2001; 98(12):3456-3464.

13. O’Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using postransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8(7):377-386.

14. Luznik L, O’Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14(6):641-650.

15. Fuchs EJ, Luznik L, Bolaños-Meade J et al. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant 2009; 43(12):969-970.

16. Fuchs EJ, Wu J, Carter S et al. Phase II Trial of Non- Myeloablative Conditioning and Partially HLA-Mismatched (HLA-Haploidentical) Bone Marrow Transplantation (BMT) for Patients With Hematologic Malignancies: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0603. Biology of Blood and Marrow Transplantation 2011; 17(2, Supplement 1):S151.

17. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010;16(4):482-489.

18. Bolaños-Meade J, Lanzkron S, Kemberling H et al. Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation (haplo-BMT) With Post-Transplant High-Dose Cyclophosphamide (Cy) in Patients With Severe Hemoglobinopathies. Biology of Blood and Marrow Transplantation 2011;17(2, Supplement 1):S285.

19. Brodsky RA, Luznik L, Bolaños-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant 2008; 42(8):523-527.

20. Luznik L, Bolaños-Meade J, Zahurak M et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115(16):3224-3230.